ATE257703T1 - 1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes - Google Patents

1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes

Info

Publication number
ATE257703T1
ATE257703T1 AT98950388T AT98950388T ATE257703T1 AT E257703 T1 ATE257703 T1 AT E257703T1 AT 98950388 T AT98950388 T AT 98950388T AT 98950388 T AT98950388 T AT 98950388T AT E257703 T1 ATE257703 T1 AT E257703T1
Authority
AT
Austria
Prior art keywords
adenosine
asthma
thiazoles
allergies
diabetes
Prior art date
Application number
AT98950388T
Other languages
English (en)
Inventor
Shigenori Ohkawa
Hiroyuki Kimura
Naoyuki Kanzaki
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Application granted granted Critical
Publication of ATE257703T1 publication Critical patent/ATE257703T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
AT98950388T 1997-10-27 1998-10-26 1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes ATE257703T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP29448597 1997-10-27
PCT/JP1998/004837 WO1999021555A2 (en) 1997-10-27 1998-10-26 Adenosine a3 receptor antagonists

Publications (1)

Publication Number Publication Date
ATE257703T1 true ATE257703T1 (de) 2004-01-15

Family

ID=17808383

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98950388T ATE257703T1 (de) 1997-10-27 1998-10-26 1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes

Country Status (8)

Country Link
US (2) US6436966B1 (de)
EP (1) EP1027050B1 (de)
JP (1) JPH11193281A (de)
AT (1) ATE257703T1 (de)
AU (1) AU9648098A (de)
CA (1) CA2302417A1 (de)
DE (1) DE69821132T2 (de)
WO (1) WO1999021555A2 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE257703T1 (de) * 1997-10-27 2004-01-15 Takeda Chemical Industries Ltd 1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes
WO1999064418A1 (en) * 1998-06-05 1999-12-16 Novartis Ag Aryl pyridinyl thiazoles
IL146105A (en) 1999-04-23 2005-09-25 Tadeda Pharmaceutical Company 5-pyridyl-1, 3-azole compounds, process for producing the same and use therefor
CA2381215A1 (en) * 1999-08-06 2001-02-15 Takeda Chemical Industries, Ltd. P38map kinase inhibitors
AU7559200A (en) * 1999-10-12 2001-04-23 Japan Tobacco Inc. Hypertriglyceridemia remedies and antiobestics
ES2254238T3 (es) 1999-10-27 2006-06-16 Novartis Ag Compuestos de tiazol e imidazo(4,5-b)piridina y su uso farmaceutico.
HK1050190A1 (zh) * 1999-11-22 2003-06-13 Smithkline Beecham Plc 咪唑衍生物和它们做为raf激酶抑制剂的用途
JP2003525291A (ja) * 2000-03-01 2003-08-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ２，４−二置換チアゾリル誘導体
GB0005357D0 (en) 2000-03-06 2000-04-26 Smithkline Beecham Plc Compounds
EP1268474A2 (de) 2000-03-30 2003-01-02 Takeda Chemical Industries, Ltd. Substituierte 1,3-thiazol-verbindungen, ihre herstellung und verwendung
EP1308441B1 (de) * 2000-08-11 2009-10-07 Eisai R&D Management Co., Ltd. 2-aminopyridin-verbindungen und ihre verwendung als medikamente
US6645990B2 (en) 2000-08-15 2003-11-11 Amgen Inc. Thiazolyl urea compounds and methods of uses
EP1318992B1 (de) 2000-09-21 2005-07-27 Smithkline Beecham Plc Imidazolderivate als raf-kinase-inhibitoren
GB0028383D0 (en) 2000-11-21 2001-01-03 Novartis Ag Organic compounds
AU2002221080A1 (en) 2000-12-08 2002-06-18 Masami Kusaka Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparingthe same and use thereof
GB0102668D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
WO2002062792A1 (en) * 2001-02-02 2002-08-15 Takeda Chemical Industries, Ltd. Jnk inhibitor
JP2004530700A (ja) * 2001-05-18 2004-10-07 エンダシア，インコーポレイテッド Ａ１アデノシン及びｐ２ｘプリン受容体拮抗薬を使用する方法及び製剤
GB0112348D0 (en) * 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
EP1432703A1 (de) * 2001-09-05 2004-06-30 Smithkline Beecham Plc Heterocycle-carboxamide derivate als raf kinase inhibitoren
AU2002349705A1 (en) 2001-12-03 2003-06-17 Japan Tobacco Inc. Azole compound and medicinal use thereof
AR038966A1 (es) * 2002-03-18 2005-02-02 Solvay Pharm Bv Derivados de tiazol que tienen actividad antagonista, agonista o agonista parcial de cb1
AU2003260810A1 (en) * 2002-09-18 2004-04-08 Pfizer Products Inc. Triazole derivatives as transforming growth factor (tgf) inhibitors
WO2004026863A1 (en) 2002-09-18 2004-04-01 Pfizer Products Inc. Novel oxazole and thiazole compounds as transforming growth factor (tgf) inhibitors
DE602004028800D1 (en) * 2003-02-07 2010-10-07 Daiichi Sankyo Co Ltd Pyrazolderivat
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
GB0326601D0 (en) * 2003-11-14 2003-12-17 Novartis Ag Organic compounds
BRPI0418082B8 (pt) * 2003-12-26 2021-05-25 Kyowa Hakko Kirin Co Ltd derivados de tiazol úteis como antagonistas de receptor de adenosina a2a
WO2005099673A1 (en) * 2004-04-13 2005-10-27 Icagen, Inc. Polycylic thiazoles as potassium ion channel modulators
KR20070054669A (ko) * 2004-09-22 2007-05-29 하. 룬트벡 아크티에 셀스카브 2-아실아미노티아졸 유도체
US20100280023A1 (en) * 2005-06-23 2010-11-04 Kyowa Hakko Kogyo Co., Ltd. Thiazole derivatives
CA2617817C (en) 2005-08-02 2014-05-27 Kyowa Kirin Co., Ltd. Thiazole derivatives for treating or preventing sleep disorders
EA015034B1 (ru) 2005-09-13 2011-04-29 Янссен Фармацевтика Н.В. 2-анилин-4-арилзамещенные тиазольные производные
WO2008021338A2 (en) * 2006-08-15 2008-02-21 Wyeth Tricyclic oxazolidone derivatives useful as pr modulators
TW200815428A (en) * 2006-08-15 2008-04-01 Wyeth Corp Oxazolidone derivatives as PR modulators
PE20110341A1 (es) 2006-08-15 2011-06-21 Novartis Ag COMPUESTOS HETEROCICLICOS QUE MODULAN LA ACTIVIDAD DE LA ESTEROIL-CoA-DESATURASA
JO2784B1 (en) 2007-10-18 2014-03-15 شركة جانسين فارماسوتيكا ان. في 5,3,1 - Triazole substitute derivative
ES2424023T3 (es) 2007-10-18 2013-09-26 Janssen Pharmaceutica N.V. 1,2,4-triazoles trisustituidos
BRPI0820722A2 (pt) 2007-12-20 2015-06-16 Novartis Ag Derivados de tiazol usados como inibidores de pi 3 cinases
PE20091473A1 (es) 2008-02-20 2009-10-23 Novartis Ag Heterociclos como inhibidores de esteaoril-coa desaturasa
CA2714662C (en) 2008-03-19 2016-05-10 Janssen Pharmaceutica Nv Trisubstituted 1,2,4-triazoles as nicotinic acetylcholine receptor modulators
CL2009001125A1 (es) 2008-05-09 2011-02-11 Janssen Pharmaceutica Nv Compuestos derivados de pirazol trisustituido, moduladores alostericos positivos de los receptores ach nicotinicos; composicion farmaceutica que los comprende; proceso de preparacion de la composicion; y su uso en el tratamiento de enfermedades de snc o inflamatorias.
JP2011528363A (ja) * 2008-07-16 2011-11-17 キング・ファーマシューティカルズ・リサーチ・アンド・デベロプメント・インコーポレイティッド アテローム性動脈硬化症の治療
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
TWI435874B (zh) 2008-10-31 2014-05-01 Toray Industries 環己烷衍生物及其醫藥用途
EP2198710A1 (de) 2008-12-19 2010-06-23 Bayer CropScience AG Verwendung von 5-Pyridin-4yl-(1,3)Thiazole zur Bekämpfung phytopathogener Pilze
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
WO2012015027A1 (ja) * 2010-07-30 2012-02-02 東レ株式会社 神経障害性疼痛の治療剤又は予防剤
DE102011083259A1 (de) * 2011-09-23 2013-03-28 Beiersdorf Ag Alkylamidothiazole, deren kosmetische oder dermatologische Verwendung sowie kosmetische oder dermatologische Zubereitungen mit einem Gehalt an solchen Alkylamidothiazolen
JP6522602B2 (ja) 2013-07-02 2019-05-29 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｒｏｃｋ阻害剤としての三環式ピリド−カルボキサミド誘導体
TW201506024A (zh) 2013-07-02 2015-02-16 必治妥美雅史谷比公司 作為有效ｒｏｃｋ抑制劑的三環甲醯胺衍生物
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
ES2578363B1 (es) 2015-01-22 2017-01-31 Palobiofarma, S.L. Moduladores de los receptores A3 de adenosina
WO2018045906A1 (zh) * 2016-09-08 2018-03-15 四川科伦博泰生物医药股份有限公司 2-酰氨基噻唑类衍生物及其制备方法与用途
ES2676535B1 (es) 2017-01-20 2019-04-29 Palobiofarma Sl Moduladores de los receptores a3 de adenosina
CN109293652B (zh) * 2017-07-24 2021-10-22 四川科伦博泰生物医药股份有限公司 一种取代的噻唑衍生物及其用途
CN107400124A (zh) * 2017-09-14 2017-11-28 刘双伟 一种烟酰胺类化合物、合成路线及其在制备抗过敏药物中的应用
TWI904906B (zh) 2020-08-24 2025-11-11 美商達薩瑪治療公司 Sarm1之抑制劑

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2828091A1 (de) * 1978-06-27 1980-01-10 Boehringer Sohn Ingelheim 4-substituierte thiazoloxamsaeuren sowie ihre salze und ester
US4251535A (en) * 1978-08-29 1981-02-17 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl-2-nitroimidazoles
US4199592A (en) * 1978-08-29 1980-04-22 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl-2-nitroimidazoles
DE2856909A1 (de) 1978-12-28 1980-07-17 Schering Ag Neue imidazolderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
JPS6058981A (ja) * 1983-09-09 1985-04-05 Takeda Chem Ind Ltd ５−ピリジル−１，３−チアゾ−ル誘導体，その製造法およびそれを含んでなる医薬組成物
EP0149884B1 (de) * 1983-09-09 1992-12-16 Takeda Chemical Industries, Ltd. 5-Pyridyl-1,3-Thiazol-Derivate, ihre Herstellung und Anwendung
DE3601411A1 (de) * 1986-01-20 1987-07-23 Nattermann A & Cie 3-amino-1-(2-thiazolyl)-2-pyrazoline, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
CA2009925C (en) * 1989-02-14 2002-10-01 Koichi Kondo Method for enhancement of chemiluminescence
DE69132006T2 (de) * 1990-11-30 2000-08-03 Otsuka Pharmaceutical Co., Ltd. Thiazolederivate als inhibitoren von aktivem sauerstoff
JP2600644B2 (ja) * 1991-08-16 1997-04-16 藤沢薬品工業株式会社 チアゾリルベンゾフラン誘導体
JPH0570446A (ja) * 1991-09-13 1993-03-23 Taisho Pharmaceut Co Ltd Ｎ−チアゾリルスルホンアミド誘導体
GB9201692D0 (en) 1992-01-27 1992-03-11 Smithkline Beecham Intercredit Compounds
WO1993020061A1 (en) * 1992-04-01 1993-10-14 The University Of Toledo 4-[4'-piperidinyl or 3'-pirrolidinyl] substituted imidazoles as h3-receptor antagonists and therapeutic uses thereof
US5486526A (en) * 1992-04-01 1996-01-23 The University Of Toledo Histamine H3 -receptor antagonists and therapeutic uses thereof
AU3884893A (en) * 1992-04-10 1993-11-18 Merck Frosst Canada Inc. Thiazole-substituted benzyl alcohols as leukotriene antagonists
US5670527A (en) * 1993-07-16 1997-09-23 Smithkline Beecham Corporation Pyridyl imidazole compounds and compositions
US5783664A (en) * 1993-09-17 1998-07-21 Smithkline Beecham Corporation Cytokine suppressive anit-inflammatory drug binding proteins
WO1995011681A1 (en) * 1993-10-29 1995-05-04 Merck & Co., Inc. Human adenosine receptor antagonists
US5646156A (en) 1994-04-25 1997-07-08 Merck & Co., Inc. Inhibition of eosinophil activation through A3 adenosine receptor antagonism
US5620999A (en) * 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
US5739143A (en) * 1995-06-07 1998-04-14 Smithkline Beecham Corporation Imidazole compounds and compositions
US6001866A (en) * 1995-10-05 1999-12-14 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
US5972980A (en) * 1995-10-05 1999-10-26 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
AU6966696A (en) * 1995-10-05 1997-04-28 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
US5717100A (en) * 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
US6083949A (en) * 1995-10-06 2000-07-04 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
ES2205167T3 (es) * 1996-01-11 2004-05-01 Smithkline Beecham Corporation Nuevos compuestos de imidazol sustituidos.
WO1997033879A1 (en) 1996-03-15 1997-09-18 Merck & Co., Inc. Compounds and methods for selectively inhibiting activation of the human a3 adenosine receptor
JP2000507558A (ja) * 1996-03-25 2000-06-20 スミスクライン・ビーチャム・コーポレイション Ｃｎｓ損傷についての新規な治療
EP0889887A4 (de) * 1996-03-25 2003-06-11 Smithkline Beecham Corp Behandlung von verletzungen des zentralen nervensystems
WO1997045425A1 (en) * 1996-05-27 1997-12-04 Fujisawa Pharmaceutical Co., Ltd. New indolyl and benzofuranyl carboxamides as inhibitors of nitric oxide production
WO1998007425A1 (en) * 1996-08-21 1998-02-26 Smithkline Beecham Corporation Imidazole compounds, compositions and use
JPH1087490A (ja) * 1996-09-10 1998-04-07 Sagami Chem Res Center インターロイキン６生産抑制剤、骨吸収抑制剤、抗骨粗鬆症剤、及びチアゾール化合物
US5891892A (en) * 1996-10-29 1999-04-06 Warner-Lambert Company Small molecule biaryl compounds as inhibitors of endothelin converting enzyme
JP2001504490A (ja) * 1996-11-20 2001-04-03 メルク エンド カンパニー インコーポレーテッド トリアリール置換イミダゾール、そのような化合物を含む組成物及び使用方法
IL132318A0 (en) * 1997-04-24 2001-03-19 Ortho Mcneil Pharm Inc Substituted imidazoles useful in the treatment of inflammatory diseases
WO1999003837A1 (en) * 1997-06-30 1999-01-28 Ortho-Mcneil Pharmaceutical, Inc. 2-substituted imidazoles useful in the treatment of inflammatory diseases
JPH11145279A (ja) * 1997-10-27 1999-05-28 Shijie Xianjin Jiti Electric Co Ltd 窒化シリコン保護膜のピンホール除去方法
ATE257703T1 (de) * 1997-10-27 2004-01-15 Takeda Chemical Industries Ltd 1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes

Also Published As

Publication number Publication date
DE69821132T2 (de) 2004-10-21
US6436966B1 (en) 2002-08-20
EP1027050B1 (de) 2004-01-14
AU9648098A (en) 1999-05-17
EP1027050A2 (de) 2000-08-16
DE69821132D1 (de) 2004-02-19
CA2302417A1 (en) 1999-05-06
WO1999021555A3 (en) 1999-07-22
US6620825B1 (en) 2003-09-16
JPH11193281A (ja) 1999-07-21
WO1999021555A2 (en) 1999-05-06

Similar Documents

Publication Publication Date Title
ATE257703T1 (de) 1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes
DE69926806D1 (de) N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
DE69926919D1 (de) N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
ATE307798T1 (de) Glucagon antagonisten/inverse agonisten
TR200100137T2 (tr) Obesitenin ve başka bozuklukların tedavisinde yararlı nöropeptit Y Y5 reseptörü için ligandlar olarak N-ikameli aminotetralinler.
DE69706407D1 (de) META-SUBSTITUIERTE PHENYLENDERIVATE UND IHRE VERWENDUNG ALS ALPHAvBETA3 INTERGRIN-ANTAGONISTEN ODER INHIBITOREN
DE69414398D1 (de) Heterocyclische neurokinin-antagonisten
IL96891A0 (en) Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them
WO1997020823A3 (en) 2-amino quinazoline derivatives as npy receptor antagonists
NZ516599A (en) 2-arylimino-2,3-dihydrothiazoles, and their use thereof as somatostatin receptor ligands
DE60037726D1 (de) Carbonsäurederivate die die bindung von integrinen an ihre rezeptoren hemmen
SE9703414D0 (sv) New compounds
HK1044483A1 (zh) Il-8受体拮抗剂
ATE178886T1 (de) 1-aryl-2-acylamino-ethan-verbindungen und ihre verwendung als neurokinin- insbesondere als neurokinin-1-antagonisten
EE200100520A (et) N-(2-fenüül-4-aminobutüül)-1-naftamiidid neurokiniin-1-retseptori antagonistidena
ES2088128T3 (es) Aminosulfonilureas inhibidoras de acat.
NO963331L (no) 5-Heteroarylindol-derivater som benzodiazepin-reseptorsete-agonister og antagonister
ATE254122T1 (de) Indolderivate als 5-ht1b und 5-ht1d agonisten
ATE189894T1 (de) Naphthamidderivate von 3-beta-amino azabicyclooctan oder nonan als antipsychotische arzneimittel
DE3578125D1 (de) Formulierung von entzuendungshemmenden arzneimitteln.
HK1044717A1 (zh) Il-8受体拮抗剂
FI971831A0 (fi) Heterosyklillä substituoituja propeenihappojohdannaisia NMDA-antagonisteina
PT1165595E (pt) Derivados de acidos biliares especificos do figado provenientes do antagonista do glicocorticoide ru486
DE69916103D1 (de) 3-alkoxylbenzylaminderivate und ihre verwendung als arzneimittel zur behandlung von schizophrenie
NO924701L (no) Amid-bundete pyridyl-benzosyrederivater for behandling avleukotrien-relaterte sykdommer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties